Medtronic Diabetes Customer Service in Switzerland
If you need assistance regarding Medtronic diabetes products or ordering supplies in Switzerland, you have several dedicated customer service channels available.
Technical Support: For urgent technical issues or emergencies with your Medtronic diabetes device, you can reach the technical hotline 24/7.
Product Information / Orders: For orders, insurance queries, or general product questions, use the dedicated Medtronic Diabetes Switzerland email or call during office hours[1][2][6].
Mailing Address
Medtronic (Schweiz) AG
Weltpoststrasse 5
3015 Bern
Further Help
For issues related to orders (e.g., returns or consignment), you can also contact: [email protected][8].
Tip: Always have your device serial number and customer information ready when contacting support to speed up inquiry handling.
If you are a healthcare professional, there are additional direct lines—contact your designated Medtronic representative or use the technical hotline for urgent needs[1][2].
Sorry I meant type 1. Gene editing can cure type 1 & will be available within 5 years. The defective gene is known. Just as ‘test tube babies’ were considered impossible & witchcraft in 1977, IVF has come a long way since.
Try google if you don’t believe me, this has been public knowledge since August 25
Any reliable sources for that information? I’m certainly not getting my hopes up as I been repeatedly told in the 63 years since I was diagnosed that a cure was just around the corner.
1983-5 I was involved in a primitive gene editing project. Thirty years later the CRISPR system came to fruition.
Ideas are cheap, getting them to work is the hard part.
I know the speed of advances in higher today and AI will accelerate that. However, whilst hype might impress financial markets it can be poison for patients.
“A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells that can slip past the immune system’s mistaken attacks. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs—and it might even lead to a future cure for the disease, researchers say.”
Diabetes: progress by UNIGE and HUG towards an insulin-free future
An important step has been taken in Geneva against type 1 diabetes. An innovative hydrogel used on mice paves the way for a bioartificial pancreas to do without insulin injections in the future, the University of Geneva (UNIGE) said on Monday.
It must promote the survival of insulin-producing cells transplanted into the body. This approach goes beyond the pancreatic islets tested so far, explain the UNIGE and the Geneva University Hospitals (HUG).
These often cause rejection and, in the liver, inflammation and insufficient blood supply. Amniogel makes it possible to circumvent these obstacles, according to this study led by UNIGE professor Ekaterine Berishvili and published in the journal Trends in biotechnology.
Derived from the human amniotic membrane, it promotes a microvascular network before a transplant. Then, the connection to the host’s bloodstream is facilitated, allowing the graft to function.
This freeze results in “a protective environment,” explains Berishvili. The disc-shaped grafts with a diameter of 9 mm allowed normal blood sugar levels in diabetic mice for at least 100 days.
The next step, before clinical application, will require that they be larger or in greater numbers to be used in humans. Beyond diabetes, Amniogel could be exploited to accommodate other cells, paving the way for other transplant care.
Well I certainly am pleased that money is being spent on researching better treatments for T1D. Big Pharma hasn’t spent a penny in the past decades, other than on extending their patents.
I suspect they have spent 100’s of millions trying to find better treatments…
Original patents expired in the 1940’s, most of the more modern patients have also expired, it’s the complexity of manufacture that is holding back generics, rather than patents.